Top

Published in:

Open Access 01-08-2015 | Invited Review

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

Authors: Axel S. Merseburger, Peter Hammerer, Francois Rozet, Thierry Roumeguère, Orazio Caffo, Fernando Calais da Silva, Antonio Alcaraz

Published in: World Journal of Urology | Issue 8/2015

Abstract

Background

A growing number of treatment options exist to treat metastatic castrate-resistant prostate cancer (mCRPC), and with these newer options, many questions about optimising treatment remain unanswered. One recommendation that may potentially be overlooked by practitioners is that androgen deprivation therapy (ADT) should be maintained when CRPC develops and when treatment with any of the newer agents is initiated.

Aim

However, to emphasise this recommendation, it is valuable to interrogate the evidence for maintaining ADT in different clinical situations.

Outcome

This statement, reflecting the views of the authors, provides a discussion of this evidence and the rationale behind the recommendation that ADT should be continued in CRPC.

Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479PubMedCrossRef

Cookson MS, Roth BJ, Dahm P et al (2013) Castration-resistant prostate cancer: AUA guideline

NCCN (2014) NCCN clinical practice guidelines in oncology. Prostate Cancer

Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992PubMedCrossRef

Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148PubMedCentralPubMedCrossRef

Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187–1197PubMedCrossRef

Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424–433PubMedCentralPubMedCrossRef

Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411–422PubMedCrossRef

Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223PubMedCrossRef

10.

de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147–1154PubMedCrossRef

11.

Morote J, Orsola A, Planas J et al (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178(4):1290–1295PubMedCrossRef

12.

Alcaraz A (2008) Management of the hormone sensitivity of prostate cancer: where are we now? Eur Urol 54(2):247–250PubMedCrossRef

13.

Manni A, Bartholomew M, Caplan R et al (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9):1456–1466PubMed

14.

Mostaghel EA, Page ST, Lin DW et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67(10):5033–5041PubMedCrossRef

15.

Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447–4454PubMedCentralPubMedCrossRef

16.

Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O (2014) Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 40(3):426–433PubMedCrossRef

17.

Philips B, Ball C, Sackett D et al (2009) Oxford Centre for evidence-based medicine levels of evidence

18.

Attard G, Belldegrun AS, de Bono JS (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96(9):1241–1246PubMedCrossRef

19.

Efstathiou E, Titus M, Tsavachidou D et al (2012) Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 30(6):637–643PubMedCentralPubMedCrossRef

20.

Soifer HS, Souleimanian N, Wu S et al (2012) Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 287(6):3777–3787PubMedCentralPubMedCrossRef

21.

O’Donnell A, Judson I, Dowsett M et al (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12):2317–2325PubMedCentralPubMed

22.

Ryan CJ, Peng W, Kheoh T et al (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17(2):192–198PubMedCentralPubMedCrossRef

23.

Sonpavde G, Attard G, Bellmunt J et al (2011) The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 60(2):270–278PubMedCrossRef

24.

Merseburger AS, Kuczyk MA, Wolff JM (2013) Pathophysiology and therapy of castration-resistant prostate cancer. Der Urologe Ausg A 52(2):219–225PubMedCrossRef

25.

Tyrrell CJ, Kaisary AV, Iversen P et al (1998) A randomised comparison of ‘Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 33(5):447–456PubMedCrossRef

26.

Wirth MP, See WA, McLeod DG et al (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172:1865–1870PubMedCrossRef

27.

Visakorpi T, Hyytinen E, Koivisto P et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4):401–406PubMedCrossRef

28.

Bubendorf L, Kononen J, Koivisto P et al (1999) Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59(4):803–806PubMed

29.

Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y (2010) Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70(7):745–754PubMedCrossRef

30.

Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102(17):6201–6206PubMedCentralPubMedCrossRef

31.

Belikov S, Oberg C, Jaaskelainen T, Rahkama V, Palvimo JJ, Wrange O (2013) FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide). Mol Cell Endocrinol 365(1):95–107PubMedCrossRef

32.

Lee GT, Jung YS, Ha YS, Kim JH, Kim WJ, Kim IY (2013) Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Cancer Sci 104(8):1027–1032PubMedCrossRef

33.

Efstathiou E, Titus M, Wen S et al (2014) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. doi:10.1016/j.eururo.2014.05.005

34.

Tran C, Ouk S, Clegg NJ et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928):787–790PubMedCentralPubMedCrossRef

35.

Smith MR, Borre M, Rathenborg P et al (2013) Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). J Clin Oncol 31(15):5001

36.

Bong GW, Clarke HS, Hancock WC, Keane TE (2008) Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer. Urology 71(6):1177–1180PubMedCrossRef

37.

Shamash J, Davies A, Ansell W et al (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98:22–24PubMedCentralPubMedCrossRef

38.

Taylor CD, Elson P, Trump DL (1993) Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 11(11):2167–2172PubMed

39.

Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M (1994) Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol 12(9):1868–1875PubMed

40.

Lee JL, Eun Kim J, Ahn JH et al (2011) Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. Am J Clin Oncol 34(2):140–144PubMed

41.

Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502–1512PubMedCrossRef

42.

Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148–1159PubMedCentralPubMedCrossRef

43.

Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14(2):149–158PubMedCrossRef

44.

Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31(30):3800–3806PubMedCentralPubMedCrossRef

45.

Sydes MR, Parmar MK, Mason MD et al (2012) Flexible trial design in practice—stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168PubMedCentralPubMedCrossRef

Title: Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?
Authors: Axel S. Merseburger
Peter Hammerer
Francois Rozet
Thierry Roumeguère
Orazio Caffo
Fernando Calais da Silva
Antonio Alcaraz
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 8/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1406-2

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

Abstract

Background

Aim

Outcome

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Aim

Outcome

Please log in to get access to this content

Other articles of this Issue 8/2015

Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy

Utility of urodynamics in the management of asymptomatic tethered cord in children

Influence of metformin use on PSA values, free-to-total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

Ten year experience of retroperitoneal laparoscopic resection for pheochromocytomas: A dual-centre study of 72 cases

The accuracy of renal tumor biopsy: analysis from a national prospective study

Change in storage symptoms following laser prostatectomy: comparison between photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP)